Abstract: In one aspect of the invention, the present invention discloses and claims a recombinant transforming growth factor alpha (TGF ?) consisting of Sequence ID No.: 1, craving out from the whole TGF ?, and cloned for the wound healing applications. Further it discloses primers for amplifying TGF ? consisting of Sequence ID Nos.: 2 and 3, wherein sequence ID No.: 2 is forward primer, and the sequence ID No.: 3 is reserve primer for TGF ?. It further discloses a process of preparation of a vector comprising essentially of Sequence ID No.: 1, said process comprising the steps of multiplying the desired gene fragment through PCR using primers of Sequence ID No.: 2 and 3. Further, a pharmaceutical composition comprising essentially of Sequence ID No.: 1, along with additives, fillers and addendums is disclosed. Finally, it discloses a method of wound healing using the recombinant TGF ? comprising application of a pharmaceutical composition.